Renoprotective effects of combined aliskiren and valsartan in progressive diabetic nephropathy in rats

International Journal of Pharmaceutical Sciences Review and Research

Volumn 6, Issue 2, 2011, Pages 152-158

  Nyathani, Hemanth Kumar ^a   Srirangam, Prashanth ^a   Jinugu, Vidya Sagar ^a   Chinnala, Krishna Mohan ^b  

^a Vaagdevi College of Pharmacy   (India)

^b StPeter's College of Pharmacy   (India)

Author keywords

Aliskiren; Diabetic Nephropathy; Renin angiotensin system; Valsartan

Indexed keywords

ALISKIREN; CREATININE; GLUCOSE; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFICACY; FEMALE; GLOMERULOSCLEROTIC INDEX; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; KIDNEY FIBROSIS; KIDNEY MASS; MONOTHERAPY; NONHUMAN; PARAMETERS OF MEASUREMENT AND ANALYSIS; PROTEINURIA; QUANTITATIVE ANALYSIS; RAT; RENAL PROTECTION; URINE VOLUME; WISTAR RAT;

EID: 79952056028     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Stern M. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 1995; 44:369-374.
2. Eastman R, Siebert C, Harris M, Gorden P. Clinical review: implications of the Diabetes Control and complications trial. J Clin Endocrinol Metab 1993; 77: 1105-1107.
3. Turner R. The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998; 21 (Suppl 3): C35-C38.
4. Clark CJ, Lee D. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995; 332: 1210-1217.
5. Fore W. Noninsulin-dependent diabetes mellitus. The prevention of complications. Med Clin North Am 1995; 79: 287-298.
6. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2-15
7. Parving H.H, Osterby R, Ritz E: Diabetic Nephropathy. The Kidney, edited by Brenner BM, Philadelphia, WB Saunders, 2000, P.1731.
8. Jennifer L. Wilkinson-Berka. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2) 27 rat. Nephrol Dial Transplant 2001; 16: 1343-1349.
9. Michel Azizi, MD, PhD; Joël Ménard, MD. Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists. Circulation 2004; 109:2492-2499.
10. Charles R. Craig, Robert E. Stitzel, Modern Pharmacology with Clinical Applications. Fifth Edition: 156, 213, 217.
11. J Kelly. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50: 2398-2404.
12. Kelly DJ, Hepper C, Zhang Y, Jaworski K, Wilkinson-Berka JL, Gilbert RE., Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003; 52: 512-518.
13. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of Photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 1997; 45: 1559-1565.
14. Lehr HA, van der Loos CM, Teeling P, Gown AM. Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. J Histochem Cytochem 1999; 47: 119-126.